Overexpression of one or more membrane-bound complement regulatory proteins (mCRPs)
protects tumour cells against complement-mediated clearance by the autologous humoral …

The efficacy of cancer-immunotherapy with complement-activating monoclonal antibodies is
limited by over-expression of one or more membrane-bound complement regulatory …

Anti-tumor monoclonal antibody therapy represents one of the earliest targeted therapy in
clinical cancer care and has achieved a great clinical promise. Complement activation …

Monoclonal antibodies (mAbs) are being increasingly used in cancer therapy owing to their
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …

It has long been understood that the control and surveillance of tumors within the body
involves an intricate dance between the adaptive and innate immune systems. At the center …

Complement-dependent cytotoxicity (CDC) is one of the effector mechanisms mediated by
therapeutic anticancer monoclonal antibodies (mAbs). However, the efficacy of antibodies is …

MAb-mediated immunotherapy offers a potential tool for destroying metastasizing colorectal
tumor cells. Promising results have been obtained by using xenograft models. However …

Membrane-bound complement regulatory proteins (mCRPs) play an important role in the
protection of cells from complement-mediated injury. It is now apparent that malignant tumor …

Complement-inhibitory proteins expressed on cancer cells can provide protection from
antitumor antibodies and may potentially modulate the induction of an immune response to …

The complement system is a powerful tool of the innate immune system to eradicate
pathogens. Both in vitro and in vivo evidence indicates that therapeutic anti-tumor …